TRAILR1/TNFRSF10A Antibody (DR-4-02) - Azide and BSA Free

Immunocytochemistry/Immunofluorescence: TRAIL R1/TNFRSF10A Antibody (DR-4-02) - Azide Free [NBP2-31343] - Staining (confocal microscopy) of HeLa human cervix carcinoma cell line transfected with TRAIL-R1 expression plasmid using anti-human TRAIL-R1 (DR-4-02).

Flow Cytometry: TRAIL R1/TNFRSF10A Antibody (DR-4-02) - Azide Free [NBP2-31343] - Using the PE direct conjugate Surface staining of CD261-transfected HEK-293 cells with anti-CD261/TRAIL-R1 (DR-4-02) PE.

Analysis of TRAIL-R1 expression on the surface of hematopoietic cell lines.Cells were stained with purified anti-TRAIL-R1 purified antibodies (low endotoxin) followed by Goat anti-mouse IgG PE.

• Reactivity: Hu
• Applications: Flow, Func, ICC/IF, IP, CyTOF-ready
• Clone: DR-4-02
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: 1.0 mg/ml

TRAILR1/TNFRSF10A Antibody (DR-4-02) - Azide and BSA Free Summary

• Additional Information: Clone DR-4-02 was used by HLDA to establish CD designation.
• Immunogen: Fusion protein (Human). Fusion protein containing the extracellular part of DR4 and the constant part of the heavy chain of the human IgG1 (NM_003844.3).
• Localization: Cell Membrane
• Specificity: The mouse monoclonal antibody DR-4-02 recognizes an extracellular epitope of TRAIL-R1 (DR4), a human death receptor 4 expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) and in a variety of tumour-derived cell lines.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF10A
• Purity: Protein A purified
• Endotoxin Note: Endotoxin level is less than 0.01 EU/ug of the protein

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 2-4 ug/ml
  • Functional
  • Immunocytochemistry/ Immunofluorescence
  • Immunoprecipitation
• Application Notes: Soluble antibody DR-4-02 blocks apoptosis triggered by a ligand (TRAIL). Plastic-immobilized (cross-linked) DR-4-02 antibody induces apoptosis in sensitive cells. Recommended dilution of antibody: 2-3 ug/ml in cultivation medium Final concentration of TRAIL: 20-200 ng/ml It is recommended to add the antibody 15 min before addition of TRAIL. This antibody is CyTOF ready.

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: Phosphate buffered saline (PBS), pH 7.4
• Preservative: No Preservative
• Concentration: 1.0 mg/ml
• Purity: Protein A purified

Alternate Names for TRAILR1/TNFRSF10A Antibody (DR-4-02) - Azide and BSA Free

• APO2
• CD261 antigen
• CD261
• cytotoxic TRAIL receptor
• Death receptor 4
• DR4 TRAIL receptor 1
• DR4
• TNF-related apoptosis inducing ligand receptor 1
• TNF-related apoptosis-inducing ligand receptor 1
• TNFRSF10A
• TRAIL R1
• TRAILR1
• TRAIL-R1
• TRAILR-1
• TRAILR1MGC9365
• tumor necrosis factor receptor superfamily member 10A
• tumor necrosis factor receptor superfamily, member 10a

Background

Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified and designated DR4 (for death receptor 4). The ligand for this novel death receptor has been identified and termed TRAIL, which is a new member in the TNF family. DR4 is also called TRAIL receptor 1(TRAIL R1). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates apoptosis and NF kB activation in many tissues and cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRAILR1/TNFRSF10A Antibody (NBP2-31343)(2)

Publications using NBP2-31343

• Van der Meer JMR, de Jonge PKJD, van der Waart AB et al. CD34(+) progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg(null) mice OncoImmunology 2021-10-07 [PMID: 34616589]
• Sarkar S, Faller DV. Telomere-Homologous G-Rich Oligonucleotides Sensitize Human Ovarian Cancer Cells to TRAIL-Induced Growth Inhibition and Apoptosis Nucleic Acid Ther 2013 May 2 2013-05-02 [PMID: 23634944]
  
  Details:
  This citation used the FITC version of this antibody.

Bioinformatics

• Gene Symbol: TNFRSF10A